Advertisement

Topics

Is APHINITY the End of the Line for Trastuzumab Add-ons?

11:38 EDT 5 Jun 2017 | Medscape

The addition of pertuzumab to standard trastuzumab therapy in patients with early HER2-positive breast cancer led to modest improvements and increased side effects in the APHINITY trial.
Medscape Medical News

Original Article: Is APHINITY the End of the Line for Trastuzumab Add-ons?

NEXT ARTICLE

More From BioPortfolio on "Is APHINITY the End of the Line for Trastuzumab Add-ons?"

Quick Search
Advertisement
 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...